NCT04603924 - Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

February 16, 2022

Study Completion Date

February 16, 2022

Conditions

COVID-19

Interventions

DRUG

Niclosamide

Niclosamide is an antihelmintic with in-vitro antiviral activity

DRUG

Placebo

Matching hydroxypropylmethylcellulose HPMC capsules with no active ingredients

Trial Locations (8)

Caroline Institute for Clinical Research, Fayetteville

Baptist Health Research Institute, Jacksonville

AdventHealth Tampa, Tampa

Helen Keller Hospital, Sheffield

University of Missouri Health Care, Columbia

Memorial Hermann Memorial City Medical Center, Houston

University of California, Irvine, Irvine

Providence Regional Medical Center Everett, Everett